Guided by artificial intelligence and powered by a robotic platform, a system developed by MIT researchers moves a step closer to automating the production of small molecules that could be used in medicine, solar energy, and polymer chemistry.
The system, described in the August 8 issue of Science, could free up bench chemists from a variety of routine and time-consuming tasks, and may suggest possibilities for how to make new molecular compounds, according to the study co-leaders Klavs F. Jensen, the Warren K. Lewis Professor of Chemical Engineering, and Timothy F. Jamison, the Robert R. Taylor Professor of Chemistry and associate provost at MIT.
The technology “has the promise to help people cut out all the tedious parts of molecule building,” including looking up potential reaction pathways and building the components of a molecular assembly line each time a new molecule is produced, says Jensen.
“And as a chemist, it may give you inspirations for new reactions that you hadn’t thought about before,” he adds.
Other MIT authors on the Science paper include Connor W. Coley, Dale A. Thomas III, Justin A. M. Lummiss, Jonathan N. Jaworski, Christopher P. Breen, Victor Schultz, Travis Hart, Joshua S. Fishman, Luke Rogers, Hanyu Gao, Robert W. Hicklin, Pieter P. Plehiers, Joshua Byington, John S. Piotti, William H. Green, and A. John Hart.
From inspiration to recipe to finished product
The new system combines three main steps. First, software guided by artificial intelligence suggests a route for synthesizing a molecule, then expert chemists review this route and refine it into a chemical “recipe,” and finally the recipe is sent to a robotic platform that automatically assembles the hardware and performs the reactions that build the molecule.
Coley and his colleagues have been working for more than three years to develop the open-source software suite that suggests and prioritizes possible synthesis routes. At the heart of the software are several neural network models, which the researchers trained on millions of previously published chemical reactions drawn from the Reaxys and U.S. Patent and Trademark Office databases. The software uses these data to identify the reaction transformations and conditions that it believes will be suitable for building a new compound.
“It helps makes high-level decisions about what kinds of intermediates and starting materials to use, and then slightly more detailed analyses about what conditions you might want to use and if those reactions are likely to be successful,” says Coley.
“One of the primary motivations behind the design of the software is that it doesn’t just give you suggestions for molecules we know about or reactions we know about,” he notes. “It can generalize to new molecules that have never been made.”
Image Credit: Connor Coley, Felice Frankel
News This Week
The COVID-19 pandemic has prompted considerable investigation into how the SARS-CoV-2 Spike protein attaches to a human cell during the infection process, as this knowledge is useful in designing vaccines and therapeutics. Now, a [...]
Scientists have developed protein fragments—called peptides—that fit snugly into a groove on the SARS-CoV-2 Spike protein that it would normally use to access a host cell. These peptides effectively trick the virus into "shaking hands" with a replica rather than with [...]
HSE University researchers have become the first in the world to discover genetic predisposition to severe COVID-19. The results of the study were published in the journal Frontiers in Immunology. T-cell immunity is one of [...]
When SARS-CoV-2 first began spreading across the globe, not every lab was equipped to study it directly. The virus behind the current pandemic is highly pathogenic and transmissible, leading the US Centers for Disease [...]
esearchers have detailed a mechanism in the distinctive corona of Covid-19 that could help scientists to rapidly find new treatments for the virus, and quickly test whether existing treatments are likely to work with [...]
Almost half of people testing positive for coronavirus have reported symptoms of depression, according to a new study published in the International Journal of Environmental Research and Public Health. Researchers from Bangladesh, the United States [...]
A team of investigators from the Republic of China has discovered that 6 drugs previously approved by the US Food and Drug Administration (FDA) for other indications could be repurposed to treat or prevent [...]
Graphene is a layer of carbon only one atom thick. Since it was first isolated in 2004, it has found applications in strengthening materials, accelerating electronics, and boosting performance in batteries, among others. It [...]
The ongoing Covid-19 pandemic has yielded an unexpected advancement in the pharmaceutical industry with the approval of the first mRNA vaccines, which GlobalData expects will soon impact other indications. This historical landmark could have [...]
A single dose of the Pfizer coronavirus vaccine is “highly protective” after three weeks, according to a study. Researchers at the University of East Anglia (UEA) said the coronavirus vaccine developed by Pfizer and BioNTech was still effective [...]
Summary: Mice exposed to COVID-19 through the nasal passage, researchers noted a rapid and escalated attack on the brain by the virus that triggered a more severe outcome of the infection, even after the lungs [...]
GlaxoSmithKline and Germany’s CureVac have reached a €150m (£132m) agreement to develop a next generation of Covid-19 vaccines targeting new emerging variants in the pandemic. The two companies said they plan to work jointly to [...]
The great hope for drug treatments against Covid-19 – the monoclonal antibodies – are failing against variants of the virus, such as those that have emerged in South Africa and Brazil, scientists have found. [...]
Bandages are great for covering wounds, but they would be much more useful if they could also detect infections. By embedding nanosensors in the fibers of a bandage, University of Rhode Island Assistant Professor [...]